JP2022519293A5 - - Google Patents
Info
- Publication number
- JP2022519293A5 JP2022519293A5 JP2021545713A JP2021545713A JP2022519293A5 JP 2022519293 A5 JP2022519293 A5 JP 2022519293A5 JP 2021545713 A JP2021545713 A JP 2021545713A JP 2021545713 A JP2021545713 A JP 2021545713A JP 2022519293 A5 JP2022519293 A5 JP 2022519293A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- seq
- opening
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025036066A JP7904346B2 (ja) | 2019-02-04 | 2025-03-07 | コネキシン４３抗体およびその使用 |
| JP2026078137A JP2026119205A (ja) | 2019-02-04 | 2026-05-07 | コネキシン４３抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800869P | 2019-02-04 | 2019-02-04 | |
| US62/800,869 | 2019-02-04 | ||
| PCT/US2020/016606 WO2020163353A1 (en) | 2019-02-04 | 2020-02-04 | Connexin 43 antibodies and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025036066A Division JP7904346B2 (ja) | 2019-02-04 | 2025-03-07 | コネキシン４３抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519293A JP2022519293A (ja) | 2022-03-22 |
| JP2022519293A5 true JP2022519293A5 (enExample) | 2023-02-13 |
| JP7709917B2 JP7709917B2 (ja) | 2025-07-17 |
Family
ID=71947290
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545713A Active JP7709917B2 (ja) | 2019-02-04 | 2020-02-04 | コネキシン４３抗体およびその使用 |
| JP2025036066A Active JP7904346B2 (ja) | 2019-02-04 | 2025-03-07 | コネキシン４３抗体およびその使用 |
| JP2026078137A Pending JP2026119205A (ja) | 2019-02-04 | 2026-05-07 | コネキシン４３抗体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025036066A Active JP7904346B2 (ja) | 2019-02-04 | 2025-03-07 | コネキシン４３抗体およびその使用 |
| JP2026078137A Pending JP2026119205A (ja) | 2019-02-04 | 2026-05-07 | コネキシン４３抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12187794B2 (enExample) |
| EP (1) | EP3920969A4 (enExample) |
| JP (3) | JP7709917B2 (enExample) |
| KR (1) | KR20210153039A (enExample) |
| CN (2) | CN112384244B (enExample) |
| AU (3) | AU2020219112A1 (enExample) |
| CA (1) | CA3128987A1 (enExample) |
| IL (2) | IL320816A (enExample) |
| WO (1) | WO2020163353A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116854816A (zh) | 2018-04-02 | 2023-10-10 | 阿拉玛布治疗学股份有限公司 | 连接蛋白43抗体及其用途 |
| IL300245A (en) * | 2020-07-31 | 2023-03-01 | Alamab Therapeutics Inc | Anti-connexin antibody formulations |
| WO2025006774A1 (en) * | 2023-06-30 | 2025-01-02 | Alamab Therapeutics, Inc. | Method of treating osteoarthritis |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| AU2002362197A1 (en) * | 2001-12-28 | 2003-07-24 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein |
| US6745478B2 (en) | 2002-07-18 | 2004-06-08 | Delillo Dominick D. | Multi-purpose work knife |
| PT2418220T (pt) | 2003-12-10 | 2017-10-04 | Squibb & Sons Llc | Anticorpos contra interferão alfa e suas utilizações |
| CN101573131B (zh) * | 2005-02-03 | 2017-12-01 | 科达治疗有限公司 | 抗‑连接蛋白化合物及其治疗应用 |
| AU2009246640A1 (en) | 2008-05-15 | 2009-11-19 | Biogen Idec Ma Inc. | Anti-Fn14 antibodies and uses thereof |
| WO2009148613A1 (en) * | 2008-06-04 | 2009-12-10 | Coda Therapeutics, Inc. | Treatment of pain with gap junction modulation compounds |
| US8956868B2 (en) * | 2010-12-27 | 2015-02-17 | Lsip, Llc | Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor |
| WO2015027120A1 (en) * | 2013-08-21 | 2015-02-26 | Jiang Jean X | Compositions and methods for targeting connexin hemichannels |
| US9493552B2 (en) | 2013-11-15 | 2016-11-15 | China Synthetic Rubber Corporation | Therapeutic biologic for treatment of hepatocellular carcinoma |
| WO2016029191A2 (en) * | 2014-08-22 | 2016-02-25 | Auckland Uniservices Limited | Channel modulators |
| WO2017024465A1 (en) * | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AU2017224122B2 (en) * | 2016-02-26 | 2024-04-11 | The Board Of Regents Of The University Of Texas System | Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof |
| CN116854816A (zh) | 2018-04-02 | 2023-10-10 | 阿拉玛布治疗学股份有限公司 | 连接蛋白43抗体及其用途 |
| IL300245A (en) * | 2020-07-31 | 2023-03-01 | Alamab Therapeutics Inc | Anti-connexin antibody formulations |
-
2020
- 2020-02-04 AU AU2020219112A patent/AU2020219112A1/en not_active Abandoned
- 2020-02-04 EP EP20752507.2A patent/EP3920969A4/en active Pending
- 2020-02-04 CN CN202080002561.9A patent/CN112384244B/zh active Active
- 2020-02-04 IL IL320816A patent/IL320816A/en unknown
- 2020-02-04 JP JP2021545713A patent/JP7709917B2/ja active Active
- 2020-02-04 CN CN202411949862.9A patent/CN119700967A/zh active Pending
- 2020-02-04 KR KR1020217027864A patent/KR20210153039A/ko active Pending
- 2020-02-04 CA CA3128987A patent/CA3128987A1/en active Pending
- 2020-02-04 US US17/767,171 patent/US12187794B2/en active Active
- 2020-02-04 IL IL285369A patent/IL285369B2/en unknown
- 2020-02-04 WO PCT/US2020/016606 patent/WO2020163353A1/en not_active Ceased
-
2022
- 2022-08-18 AU AU2022218583A patent/AU2022218583B9/en active Active
-
2024
- 2024-11-21 US US18/955,222 patent/US20250230233A1/en active Pending
-
2025
- 2025-03-07 JP JP2025036066A patent/JP7904346B2/ja active Active
-
2026
- 2026-02-20 AU AU2026201299A patent/AU2026201299A1/en active Pending
- 2026-05-07 JP JP2026078137A patent/JP2026119205A/ja active Pending